Circulating and tumor-infiltrating immune cell profiles in cervical cancer checkpoint blockade: multi-omics biomarkers of response and resistance
Cervical cancer is a particularly suitable setting for immune-cell profiling because HPV-driven antigenicity, chemoradiotherapy-induced tissue remodeling, anti-angiogenic combinations, and repeated exposure to PD-1/PD-L1 inhibitors all shape the blood-tumor immune axis.
Immune checkpoint blockade has changed the therapeutic landscape of cervical cancer, but clinical benefit remains heterogeneous and difficult to predict with single biomarkers. Cervical cancer is a particularly suitable setting for immune-cell profiling because HPV-driven antigenicity, chemoradiotherapy-induced tissue remodeling, anti-angiogenic combinations, and repeated exposure to PD-1/PD-L1 inhibitors all shape the blood-tumor immune axis. This Mini Review discusses how circulating immune cells and tumor-infiltrating immune cells can be jointly interrogated by multi-omics technologies to identify biomarkers of response and resistance.
This sentence confidently states why cervical cancer is a suitable setting for immune‑cell profiling, highlighting the HPV-driven antigenicity and the multiple therapeutic modalities that influence the immune context, which is essential for understanding biomarkers of response to immune‑checkpoint blockade.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- A multinational cross-sectional study on human papillomavirus and cervical cancer knowledge, vaccination attitudes, and risk factors in the Middle East
- Genomic features of cervical cancer
- Screening for Cervical Cancer
- Cervical cancer: Epidemiology, risk factors and screening
- AI approach outperformed human experts in identifying cervical precancer